ADC Therapeutics S.A.
ADCT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | 0.06 | 0.33 |
| FCF Yield | -64.50% | -89.87% | -46.32% | -15.46% |
| EV / EBITDA | -0.64 | 0.13 | -0.96 | -5.31 |
| Quality | ||||
| ROIC | -53.79% | -57.52% | -29.19% | -43.39% |
| Gross Margin | 91.60% | 96.36% | 98.43% | 95.89% |
| Cash Conversion Ratio | 0.78 | 0.49 | 0.88 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -30.38% | 27.05% | – | 143.82% |
| Free Cash Flow Growth | -2.30% | 12.30% | 42.02% | -39.77% |
| Safety | ||||
| Net Debt / EBITDA | 1.25 | 1.06 | 1.83 | 1.42 |
| Interest Coverage | -2.60 | -3.58 | -3.36 | -14.27 |
| Efficiency | ||||
| Inventory Turnover | 0.32 | 0.16 | 0.27 | 0.13 |
| Cash Conversion Cycle | 126.65 | 219.89 | 96.15 | 95.14 |